Shannon Thyme Klinger - 26 Nov 2025 Form 4 Insider Report for Moderna, Inc. (MRNA)

Signature
/s/ James Dillon, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
26 Nov 2025
Transactions value $
-$13,258
Form type
4
Filing time
01 Dec 2025, 16:24:45 UTC
Previous filing
02 Sep 2025
Next filing
02 Dec 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Klinger Shannon Thyme Chief Legal Officer C/O MODERNA, INC., 325 BINNEY STREET, CAMBRIDGE /s/ James Dillon, as Attorney-in-Fact 01 Dec 2025 0001866132

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise +773 +2.74% 28.9K 26 Nov 2025 Direct F1
transaction MRNA Common Stock Tax liability -$9.26K -374 -1.29% $24.75 28.6K 26 Nov 2025 Direct F2
transaction MRNA Common Stock Options Exercise +329 +1.15% 28.9K 28 Nov 2025 Direct F1
transaction MRNA Common Stock Tax liability -$4K -160 -0.55% $25.01 28.7K 28 Nov 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Restricted Stock Units Options Exercise $0 -773 -9.99% $0.00 6.96K 26 Nov 2025 Common Stock 773 Direct F1, F3
transaction MRNA Restricted Stock Units Options Exercise $0 -329 -16.68% $0.00 1.64K 28 Nov 2025 Common Stock 329 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.
F3 25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F4 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.